Source: Shutterstock/Lukiyanova Natalia frenta

Article • MERS-CoV

Seeking answers to combat Middle East respiratory syndrome

With a case fatality rate of 35 percent, a Middle East respiratory syndrome-related coronavirus (MERS-CoV) infection – also called camel flu – is a dangerous disease.

portrait of norbert nowotny
Dr Norbert Nowotny is a professor at the Institute of Virology at the School of Veterinary Medicine in Vienna and at the College of Medicine at the Mohammed Bin Rashid University of Medicine and Health Sciences in Dubai

About seven years ago, when the virus was first isolated, mortality was close to 100 percent since only severe infections that led to the patient being in intensive care were recorded. Today the environment of each victim is epidemiologically examined. This close monitoring ‘has shown that not all MERS-CoV infections are extremely severe, particularly in younger patients the course of disease can be less damaging,’ said Austrian virologist Professor Norbert Nowotny, who updated European Hospital on these viruses at the International Meeting on Emerging Diseases and Surveillance (IMED). The first MERS case was reported in 2012, in a man who had died of severe pneumonia. A  previously unknown coronavirus, related to the SARS coronavirus, was isolated. To date, all reported MERS-CoV infections in humans have originated on the Arabian Peninsula.

Contact with dromedaries aged about three to 18 months poses the largest risk

Norbert Nowotny

However, due to international travel these spread to 257 countries. By 31 December 2018, a total of 2,279 cases were reported, 806 of those were fatal. The major symptom is severe lung disease, but the course of the infection depends on the age of the patient: the older the patient, the more severe the infection. In addition, pre-existing conditions such as diabetes and overweight are crucial factors. Nowotny was a member of the research team that discovered the virus is present in dromedaries (camels) and that the infections are a result of a zoonotic event. Almost all older dromedaries are seropositive, i.e. they were exposed to MERS-CoV at some point in their lives. Dromedary calves are protected by maternal antibodies for about three to four months; then the calves are infected with the obviously wide-spread virus. 

In dromedaries, the infection is mostly asymptomatic, some show a low-grade rhinitis. During the acute period of the infection, which lasts about one week, the animals excrete large numbers of the virus via nose and eye secretion. Transmission to humans most likely takes place during this short period and requires close contact with the animal, Nowotny pointed out. ‘Contact with dromedaries aged about three to 18 months poses the largest risk.’ However, only five percent of the infections in humans can be traced to direct contact with dromedaries – in most cases the virus spreads via person-to-person transmission.

Some questions remain unanswered

Currently, there is no commercially available vaccine. ‘In view of the rather low number of cases, a vaccine might not make sense at all,’ Nowotny suggested. People who handle dromedaries on a day to day basis might benefit from an injection but, for the population at large, it is superfluous – which includes tourists as long as they follow Nowotny’s two golden rules: ‘Don’t get too close to young dromedaries and if you ride on an adult dromedary wash your hands afterwards with any commercially available disinfectant.’ It was also suggested to vaccinate young dromedaries in order to break the infection cycle.

However, there are questions on MERS-CoV that remain to be answered: Dromedaries are infected not only on the Arabian Peninsula but also in Africa and Iran – so why have all human cases reported so far originated on the Arabian Peninsula? One theory is that there are regional genetic differences. Moreover, diagnosing the disease is not always easy, and on the Arabian Peninsula dromedaries are pets, rather than farm animals as in Africa – which means closer contact. But even the infection path among dromedaries is far from clear as Nowotny explained. ‘Is the virus limited to dromedaries or are other animals involved, such as ticks or small rodents?’ These questions the Austrian virologist is currently working to answer.


Profile:

Dr Norbert Nowotny is a professor at the Institute of Virology at the School of Veterinary Medicine in Vienna and at the College of Medicine at the Mohammed Bin Rashid University of Medicine and Health Sciences in Dubai (UAE). The virologist’s research focuses on different aspects of (primarily viral) infections of human beings, farm animals, pets, zoo animals and wild animals. Other research interests are medical and veterinary medical entomology, viral infections transmitted by mosquitos and ticks, newly identified infection diseases and zoonoses. He served as local scientific organiser and member of the scientific committee of IMED 2018 and all six previous IMED conventions.

18.06.2019

Read all latest stories

Related articles

Photo

Sponsored • Disease management

Multiplex Testing: A Solution to Manage Surge in Respiratory Illnesses as Concerns over “Multi-demic” Rise

Eunsin Bae, M.D. specializes in laboratory medicine and leads the Institute of Clinical Research at Seegene Inc. Her research focuses on microbiology, molecular biology, and hematology. Dr. Bae is…

Photo

News • Coronavirus mechanism discovered

Organ-on-a-chip reveals how SARS-CoV-2 invades blood vessels

A research group has revealed that SARS-CoV-2 disrupts the vascular endothelial barrier by suppressing the expression of Claudin-5 (CLDN5) to invade the blood vessels.

Photo

News • Deep mutational scanning for SARS-CoV-2

Preparing rapid tests for future coronavirus variants

How can rapid antigen tests be adjusted to reliably detect future variants of SARS-CoV-2? A research team funded by the National Institutes of Health is currently working on finding an answer.

Related products

Siemens Healthineers – Fast Track Real-time PCR assays

Infectious Disease

Siemens Healthineers – Fast Track Real-time PCR assays

Siemens Healthineers
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
ASP Lab Automation – SortPro Sample sorter

Sample Processing

ASP Lab Automation – SortPro Sample sorter

ASP Lab Automation AG
Subscribe to Newsletter